Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris

RCT (n=135) found rituximab superior to mycophenolate mofetil in producing sustained complete remission at 52 weeks in patients with pemphigus vulgaris (25 patients [40%] vs. 6 [10%], p<0.001), and reducing glucocorticoid use but was linked to serious adverse events.

New England Journal of Medicine